T-Cell Lymphomas: Epidemiology Forecast to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
In the 8MM, the diagnosed incident cases of TCL are expected to increase from 27,263 cases in 2020 growing at an Annual Growth Rate (AGR) of more than 2% during 2021-2030. There is an increase forecasted in the five-year diagnosed prevalent cases of TCL from 90,275 cases in 2020 at an AGR of more than 2.5%. In 2020, for the 8MM combined, adults ages 60-69 years contributed the highest proportion of the diagnosed incident cases of TCL with more than 20%, followed by the age group 70-79 years, and ages 50-59 years. In 2020, the number of diagnosed incident cases of TCL was higher in men than in women in the 8MM combined.
TCL is broadly separated into cutaneous TCL (CTCL) and peripheral TCL (PTCL). CTCL are cancers of the skin and account for 5% of all lymphomas (American Cancer Society, 2020). PTCL is a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. PTCL could be nodal such as in the lymph nodes and spleen, or extranodal such as in the gastrointestinal tract and nasal cavity. Anaplastic large-cell lymphoma (ALCL) is a major subtype that can occur in both CTCL and PTCL. This report provides an overview of the risk factors and the global and historical epidemiological trends for TCL in the eight major markets (8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and urban China).
What are the diagnosed incident cases of TCL by CD30 Expression?
In 2020, more than 20% of diagnosed incident cases of CTCL had CD30 expression and more than 60% of PTCL cases had CD30 expression in the 8MM. Proportions were identical across all markets since a proportion from the US was used as a proxy.
Diagnosed incident cases of TCL by CD30 Expression
For more segment insights, download a free report sample
What are the diagnosed incident cases of TCL by stage at diagnosis?
In the 8MM combined, the distribution shows that the majority of diagnosed incident cases of MF and SS were in stage IA, and the fewest were in stage IIIB in 2020. Italy and Spain had the highest proportion of MF and SS cases more than 50% diagnosed at stage IA, and the fewest cases diagnosed at stages IIIA and IVB. In France and Germany, most cases of MF and SS were diagnosed at stage IA, but the proportion of cases at stage IA (more than 25%) was the lowest when compared to the other 8MM. In the UK, the fewest number of cases were diagnosed at stage IVB.
What are the diagnosed incident cases of TCL in the 8MM?
In 2020, the US accounted for more than 20% of the diagnosed incident cases of TCL in the 8MM. There were more than 4,800 cases of TCL in the 5EU combined, making up more than 15%% of the cases in the 8MM in 2020. In 2020, Japan had diagnosed incident cases, accounting for more than 7% of the cases in the 8MM. In the 8MM, the number of diagnosed incident cases of TCL will grow at an Annual Growth Rate (AGR) of more than 2%, from 2020 to 2030. Of the 8MM, urban China is expected to see the largest growth, growing from 2020 to 2030 at an AGR of more than 4%. Japan is expected to see a decrease in cases, at a negative AGR of more than 0.5%. The increase in the diagnosed incident cases of TCL is attributed to the underlying demographic changes in the respective markets.
Diagnosed incident cases of TCL in the 8MM
For more regional insights, download a free report sample
Market report scope
Key stages | Stage I, Stage II, Stage III, and Stage IV |
CD30 Expression | CTCL and PTCL |
Key Countries | The US, France, Germany, Italy, Spain, the UK, Japan, and Urban China |
Scope
This report provides an in-depth analysis of the following:
- T-cell lymphomas (TCL) Epidemiology Report and Model provide an overview of the risk factors and global trends of TCL in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China). For this report, TCL are broadly separated into cutaneous TCL (CTCL) and peripheral TCL (PTCL).
- This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of TCL (CTCL and PTCL) segmented by sex and age (0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older); diagnosed five-year prevalent cases TCL; diagnosed incident cases of TCL (CTCL and PTCL) by cancer staging; and diagnosed incident cases of TCL with CD30 biomarker expression.
- The TCL Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The TCL Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global TCL market.
- Quantify patient populations in the global TCL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the TCL cancer stages that present the best opportunities for TCL therapeutics in each of the markets covered.
- Understand the magnitude of the TCL market by biomarker.
Table of Contents
Table
Figures
Frequently asked questions
-
What is the growth rate of the diagnosed incident cases of TCL?
In the eight major markets (8MM), the diagnosed incident cases of TCL are expected to increase at an Annual Growth Rate (AGR) of more than 2% during 2021-2030.
-
Which country has the highest number of diagnosed incident cases of TCL?
In 2020, the Urban China accounted for the highest number of diagnosed incident cases of TCL among the 8MM.
-
What are the diagnosed incident cases of TCL by stage at diagnosis?
In the 8MM combined, the distribution shows that the majority of diagnosed incident cases of MF and SS were in stage IA, and the fewest were in stage IIIB in 2020.
-
What are the diagnosed incident cases of TCL by CD30 Expression?
In 2020, more than 20% of diagnosed incident cases of CTCL had CD30 expression and more than 60% of PTCL cases had CD30 expression in the 8MM.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.